1. Seidman AD, Hudis C, Crown JPA: Phase II evaluation of Taxotere (RP56976 NSC 628503) as initial chemotherapy for metastatic breast cancer.Proc Am Soc Clin Oncol 12:63, 1993.
2. Eisenhauer E: Experience with docetaxel in breast cancer. In: 7th European Conf. On Clinical Oncology and Cancer Nursing, Jerusalem, 1993.
3. Ten Bokkel Huinink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J,et al: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the ORTC Early Clinical Trials Group.Ann Oncol 5:527–532, 1994.
4. Ravdin PM, Burris SM, Cooke G, Fields SM, Smith LS, Peacock N,et al: Phase II evaluation of Taxotere (RP56976) as chemotherapy for anthracycline refractory metastatic breast cancer (abstract 512) In: 8th NCI-EORTC Symp on New Drugs in Cancer Therapy: 1994.Ann Oncol 5 (5 suppl): 203, 1994.
5. Venezoni S, Zaffaroni N, Daidone MG, Benini E, Villa R, Silvestrini R: Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers.Eur J of Cancer 30A:1002–1007, 1994.